Clincosm LogoSign in Get a demo

Metastatic Castration Resistant Prostate Cancer

Showing 1 - 25 of 36
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Castration Resistant Prostate Cancer Trial in London (IMU-935)

Recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • London, United Kingdom
    Institute of Cancer Research
Jan 31, 2023

Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer, Solid Tumor Trial in United States (Nivolumab, Ipilimumab)

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • +2 more
  • San Diego, California
  • +7 more
Jan 23, 2023

Metastatic Castration Resistant Prostate Cancer Trial in India (Enzalutamide, Androgen deprivation therapy (ADT))

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Ahmedabad, India
  • +7 more
Jan 21, 2023

Metastatic Castration Resistant Prostate Cancer Trial in Worldwide (Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel)

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Rucaparib
  • Abiraterone acetate or Enzalutamide or Docetaxel
  • Birmingham, Alabama
  • +149 more
Jan 19, 2023

Metastatic Castration Resistant Prostate Cancer Trial in China (AC176)

Not yet recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Beijing, China
  • +4 more
Jan 4, 2023

Metastatic Castration Resistant Prostate Cancer Trial in Worldwide (Enzalutamide, Docetaxel, Prednisolone)

Active, not recruiting
Has Results
  • Metastatic Castration Resistant Prostate Cancer
  • Linz, Austria
  • +88 more
Dec 22, 2022

Metastatic Castration Resistant Prostate Cancer Trial in United States (LAVA-1207)

Recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • LAVA-1207
  • Tampa, Florida
  • +3 more
Nov 18, 2022

Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma Trial in United States (Part 1

Active, not recruiting
  • Hepatocellular Carcinoma
  • +11 more
  • Part 1 TPST-1120
  • +3 more
  • San Francisco, California
  • +10 more
Nov 1, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Shanghai (Fluzoparib, Enzalutamide OR abiraterone acetate With

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 23, 2022

NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +12 more
  • Tucson, Arizona
  • +26 more
Aug 1, 2022

Metastatic Castration Resistant Prostate Cancer, Prostate Tumors Trial run by the NCI (enzalutamide, CRLX101)

Terminated
Has Results
  • Metastatic Castration Resistant Prostate Cancer
  • Prostate Neoplasms
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 16, 2022

Metastatic Castration Resistant Prostate Cancer Trial in New York, Pittsburgh, Seoul (DZD2269)

Terminated
  • Metastatic Castration Resistant Prostate Cancer
  • New York, New York
  • +5 more
Jul 6, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Worldwide (Rucaparib)

Completed
Has Results
  • Metastatic Castration Resistant Prostate Cancer
  • Birmingham, Alabama
  • +148 more
Jun 14, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Worldwide (TAS3681)

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Sacramento, California
  • +38 more
May 26, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Sydney, Melbourne (Pembrolizumab, 177Lu-PSMA)

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Sydney, New South Wales, Australia
  • +3 more
May 23, 2022

Metastatic Castration Resistant Prostate Cancer Trial in United States (VERU-111)

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Golden, Colorado
  • +12 more
Mar 28, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Switzerland, United Kingdom (AZD5069, Enzalutamide 40 MG)

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Bellinzona, Switzerland
  • +3 more
Mar 18, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Atlanta, Minneapolis, Nashville (Rucaparib, Enzalutamide, Abiraterone)

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Atlanta, Georgia
  • +2 more
Jan 24, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Houston (Ac225-PSMA I&T)

Recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Ac225-PSMA I&T
  • Houston, Texas
    Excel Diagnostics and Nuclear Oncology Center
Jan 27, 2022

Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer Trial in Australia, Canada, United States (Ciforadenant,

Completed
  • Renal Cell Cancer
  • Metastatic Castration Resistant Prostate Cancer
  • Tucson, Arizona
  • +19 more
Aug 27, 2021

Metastatic Castration Resistant Prostate Cancer Trial in Los Angeles, Houston (177Lu-PSMA-617)

Terminated
Has Results
  • Metastatic Castration Resistant Prostate Cancer
  • Los Angeles, California
  • +1 more
Mar 1, 2021

Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive Trial in Meldola (177Lu-PSMA)

Unknown status
  • Metastatic Castration Resistant Prostate Cancer
  • 68Ga-PSMA PET/CT Positive
  • Meldola, FC, Italy
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumor
Feb 25, 2021

Metastatic Castration Resistant Prostate Cancer Trial in Chengdu (HC-1119)

Completed
  • Metastatic Castration Resistant Prostate Cancer
  • Chengdu, Sichuan, China
    Hinova Pharmaceuticals Inc.
Oct 30, 2020

Metastatic Castration Resistant Prostate Cancer Trial in Changsha (Enzalutamide, HC1119)

Completed
  • Metastatic Castration Resistant Prostate Cancer
  • Changsha, China
    Medical Ethics Committee of Hunan Cancer Hospital
Oct 30, 2020

Metastatic Castration Resistant Prostate Cancer Trial in Shanghai (HC1119)

Completed
  • Metastatic Castration Resistant Prostate Cancer
  • Shanghai, China
    Shanghai Changhai Hospital Ethics Committee
Oct 30, 2020